Microbix Announces Annual Meeting Voting Results

Rhea-AI Summary

Microbix (OTCQB:MBXBF / TSX:MBX) reported results from its Annual Meeting held March 25, 2026, with 27.44% of issued shares represented.

All resolutions passed; all board nominees were re-elected. Notable vote results: Jennifer Stewart received 86.07% support (13.93% withheld). Auditors Ernst & Young LLP were re-appointed with 96.66% support. Meeting materials and slides are posted on the company website and SEDAR+.

News Market Reaction – MBXBF

+3.75%

1 alert

+3.75% News Effect

On the day this news was published, MBXBF gained 3.75%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

MISSISSAUGA, ON / ACCESS Newswire / March 26, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQB:MBXBF) ("Microbix^®" or the Company"), a life sciences innovator, manufacturer, and exporter, announces the voting results from the Annual Meeting of Shareholders of the Company (the "Meeting") which was held on March 25, 2026.

At the Meeting, 27.44% of the issued and outstanding shares were represented. Shareholders voted in favour of all resolutions brought before the Meeting. Details of all resolutions that were voted upon are set out in the Management Information Circular (the "Circular") dated February 6, 2026. The Circular is available on the Company's website (https://www.microbix.com) and on SEDAR+ (https://www.sedarplus.ca).

All of the board of directors nominees listed in the Circular were re-elected as directors of Microbix. Results of the vote were as follows:

Nominee	Votes For	% Votes For	Withheld	% Withheld
Peter M. Blecher	36,372,515	99.77%	83,900	0.23%
Mark A. Cochran	36,370,515	99.76%	85,900	0.24%
Vaughn C. Embro-Pantalony	35,731,938	98.01%	724,477	1.99%
Joseph D. Renner	36,370,515	99.76%	85,900	0.24%
Martin Marino	36,370,515	99.76%	85,900	0.24%
Cameron Groome	35,793,938	98.18%	662,477	1.82%
Jennifer Stewart	31,377,765	86.07%	5,078,650	13.93%

Shareholders also approved a resolution re-appointing the Company's auditors, Ernst & Young LLP, with 96.66% of the votes cast in favour.

The slides of management's presentation at the Meeting have been posted at https://www.microbix.com.

About Microbix Biosystems Inc.

Microbix Biosystems Inc. creates proprietary biological products for human health, with over 120 skilled employees and revenues of C$ 18.6 million in its latest fiscal year (2025). It makes a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs^™) and reference materials (QUANTDx^™) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its antigens drive the antibody tests of approximately 100 diagnostics makers, while QAPs or QUANTDx are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of international distributors. Microbix is ISO 9001 & 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides IVDR-compliant CE marked products.

Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably Kinlytic^® urokinase, a biologic thrombolytic drug used to treat blood clots and reagents to support molecular diagnostic testing (e.g., its DxTM^™ for patient sample collection. Microbix is traded on the TSX and OTCQX, and headquartered in Mississauga, Ontario, Canada.

Forward-Looking Information

This news release includes "forward-looking information," as such term is defined in applicable securities laws. Forward-looking information includes, without limitation, discussions about the Meeting or its relevance, Microbix's or others' products or services, business and business results, goals or outlook, risks associated with financial results and stability, development projects such as those referenced in its presentations, regulatory compliance and approvals, access to and sales to foreign jurisdictions, engineering and construction, production (including control over costs, quality, quantity or timeliness of delivery), currency exchange rates, maintaining adequate working capital or raising new capital on acceptable terms or at all, and other similar statements about anticipated future events, conditions or results that are not historical facts. These statements reflect management's current estimates, beliefs, intentions, and expectations; they are not guarantees of future performance. Microbix cautions that all forward-looking information is inherently uncertain and actual performance may be affected by a number of material factors, many of which are beyond its control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions, and expectations expressed or implied in the forward-looking information. All statements are made as of the date of this news release and represent Microbix's judgement as of the date of this new release, and it is under no obligation to update or alter any forward-looking information except as required by applicable law.

Please visit https://microbix.com or https://www.sedarplus.ca for recent Microbix news and filings.

For further information, please contact Microbix at:

Cameron Groome, CEO (905) 361-8910

Jim Currie, CFO (905) 361-8910

Deborah Honig, Investor Relations Adelaide Capital Markets (647) 203-8793 ir@microbix.com

Copyright ^© 2026 Microbix Biosystems Inc.
Microbix^®, DxTM^™, Kinlytic^®, QAPs^™, and QUANTDx^™ are trademarks of Microbix Biosystems Inc.

SOURCE: Microbix Biosystems Inc.

View the original press release on ACCESS Newswire

FAQ

What percent turnout did Microbix (MBXBF) report at the March 25, 2026 annual meeting?

Turnout was 27.44% of issued and outstanding shares represented at the meeting. According to the company, that reflects the proportion of shares voting in person or by proxy on March 25, 2026.

Were Microbix (MBXBF) board nominees re-elected at the March 25, 2026 meeting?

Yes, all board nominees were re-elected as directors of Microbix. According to the company, each nominee received majority support, with individual vote tallies and percentages published in the meeting results.

How did director Jennifer Stewart fare in the MBXBF shareholder vote on March 25, 2026?

Jennifer Stewart received 86.07% votes for and 13.93% withheld at the meeting. According to the company, her vote total was 31,377,765 for and 5,078,650 withheld as reported.

Did Microbix (MBXBF) re-appoint auditors at the March 25, 2026 meeting and with what support?

Yes, the company re-appointed Ernst & Young LLP as auditors with 96.66% of votes cast in favour. According to the company, shareholders approved the auditor re-appointment during the meeting.

Where can investors view the Microbix (MBXBF) annual meeting materials and vote details?

Investors can access the Management Information Circular, vote results, and presentation slides on the company website and SEDAR+. According to the company, the Circular dated February 6, 2026 and slides are posted online.

What do the annual meeting results mean for MBXBF governance going forward?

The results confirm continuity of the board and auditor appointments, supporting existing governance for the near term. According to the company, re-elections and auditor re-appointment maintain current leadership and oversight following the March 25, 2026 vote.